Biocartis Group NV

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
  • TickerA14R82
  • ISINBE0974281132
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium

Analysts

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 27 September 2019

On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The sole agenda item relates to the proposed approval and ratification, in accordance with Article 556 of the Belgian Companies Code, of conditions of the convertible bonds in case of a change of control. These are standard provisions and they are in line with the market practice. Hence, we see no reason for shareholder concern and recommend to approve.

An unfavourable environment weighs on BIOCARTIS, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIOCARTIS (BE), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 6, 2019, the closing price was EUR 7.20 and its target price was estimated at EUR 6.84.

Hugo Solvet

BIOCARTIS: “Show me story” with near-term catalyst | BUY | EUR13.5 vs. EUR17 (+93%)

BIOCARTIS - BUY | EUR13.5 vs. EUR17 (+93%) “Show me story” with near-term catalyst Slow US volumes ramp-up is “operational not structural” Opportunity arising from the termination of the TMO agreement? Adjusting our estimates. New Fair Value of EUR13.5 (vs EUR17)

Cedric Duinslaeger ...
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: BCART BB, BREB BB, COFB BB, EURN BB, GBLB BB, HOMI BB, JEN BB, KPN NA, OXUR BB, PROX BB, QFG BB, SBMO NA, SOF BB, TEXF BB

Biocartis: Moving fast can cause an ugly fall Brederode: Strong results driven by its listed portfolio Cofinimmo: First steps into HC in Spain w. € 45m investment Euronav: Key take-aways IMO2020 webinar GBL: € 750m exchangeable bond for Lafarge shares Home Invest Belgium: 1H19 results: strong sales will cover DPS Jensen-Group: When I said “I do”, I didn’t mean laundry! KPN: Appointment of new CEO, Dominique Leroy Oxurion: 1H19: a setback versus rising opportunity in DR Proximus: CEO Dominique Leroy leaves for KPN Quest for Growth: NAV down 2.7%, discount up to 25% SBM Offshore: LT FPSO supply ...

Hugo Solvet

BIOCARTIS: H1 2019: delayed uptake of US consumable sales will impact FY19 sales | BUY | Under Review

BIOCARTIS - BUY | Under Review H1 2019: delayed uptake of US consumable sales will impact FY19 sales Idylla placements in-line, weak US cartridges volumes Termination of the US distribution agreement with TMO Transition to a commercial stage company reflected in the PnL Guidance lowered for the FY19

Hugo Solvet

BIOCARTIS: “Show me story” with near-term catalyst | BUY | EUR13.5 vs. EUR17 (+93%)

BIOCARTIS - BUY | EUR13.5 vs. EUR17 (+93%) “Show me story” with near-term catalyst Slow US volumes ramp-up is “operational not structural” Opportunity arising from the termination of the TMO agreement? Adjusting our estimates. New Fair Value of EUR13.5 (vs EUR17)

Cedric Duinslaeger ...
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: BCART BB, BREB BB, COFB BB, EURN BB, GBLB BB, HOMI BB, JEN BB, KPN NA, OXUR BB, PROX BB, QFG BB, SBMO NA, SOF BB, TEXF BB

Biocartis: Moving fast can cause an ugly fall Brederode: Strong results driven by its listed portfolio Cofinimmo: First steps into HC in Spain w. € 45m investment Euronav: Key take-aways IMO2020 webinar GBL: € 750m exchangeable bond for Lafarge shares Home Invest Belgium: 1H19 results: strong sales will cover DPS Jensen-Group: When I said “I do”, I didn’t mean laundry! KPN: Appointment of new CEO, Dominique Leroy Oxurion: 1H19: a setback versus rising opportunity in DR Proximus: CEO Dominique Leroy leaves for KPN Quest for Growth: NAV down 2.7%, discount up to 25% SBM Offshore: LT FPSO supply ...

Hugo Solvet

BIOCARTIS: H1 2019: delayed uptake of US consumable sales will impact FY19 sales | BUY | Under Review

BIOCARTIS - BUY | Under Review H1 2019: delayed uptake of US consumable sales will impact FY19 sales Idylla placements in-line, weak US cartridges volumes Termination of the US distribution agreement with TMO Transition to a commercial stage company reflected in the PnL Guidance lowered for the FY19

Cedric Duinslaeger ...
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: AED BB, ATEB BB, BCART BB, ECONB BB, EURN BB, GIMB BB, PNL NA, RTL BB

Aedifica: FY18-19: strong results and higher expectations Atenor: 1H19 Results: Net profit up 11.7% Biocartis: 1H19: US causes serious dent in volume ramp-up Econocom: Reiterates commitment to group restructure Euronav: On IMO2020 strategy Gimv: € 10m investment in iSTAR Medical PostNL: ACM rejects acquisition of Sandd by PostNL RTL Group: Transformation at full throttle

Victor Floc’h

BIOCARTIS: EXAS/GHDX: a stronger partner emerging for Biocartis; Q2 preview | BUY | EUR17(+61%)

BIOCARTIS - BUY | EUR17(+61%) EXAS/GHDX: a stronger partner emerging for Biocartis; Q2 preview EXAS/GHDX combination: a stronger partner for Biocartis H1 preview: slight delay in volumes offset by collaborations Slight adjustments do not impact our FV

A director sold 10,000 shares at 14.040EUR and

A director at Biocartis Group Nv sold 10,000 shares at 14.040EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

An unfavourable environment weighs on BIOCARTIS, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIOCARTIS (BE), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 6, 2019, the closing price was EUR 7.20 and its target price was estimated at EUR 6.84.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 27 September 2019

On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The sole agenda item relates to the proposed approval and ratification, in accordance with Article 556 of the Belgian Companies Code, of conditions of the convertible bonds in case of a change of control. These are standard provisions and they are in line with the market practice. Hence, we see no reason for shareholder concern and recommend to approve.

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 10 May 2019

In general, BIOCARTIS is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting.  Under ITEM 6, the board of directors seeks approval of the Company's remuneration report. Although amounts at stake are very moderate compared to sector and market practice, ECGS has concerns over the poor disclosure of the company and the lack of LTI component. Thus ECGS recommends to vote OPPOSE.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch